Aethl Bio, Inc.

08/24/2026

A study on hypoxia-driven biofilm formation by Supardy and Kumar offers clear insight into why diabetic foot ulcers are so difficult to resolve.

When wound tissue lacks sufficient oxygen, bacteria quickly attach and build a protective barrier known as a biofilm. This matrix prevents antibiotics from reaching the infection, driving high rates of recurrence. This research reinforces that surface-level treatment is rarely enough, and points to the notion that addressing non-healing wounds should also focus on targeting the biological conditions beneath the surface.

At Aethl, we believe understanding these underlying mechanisms is essential to building better recovery frameworks.

Read the full study here: https://pmc.ncbi.nlm.nih.gov/articles/PMC12715951/

Diabetic Foot Ulcers (DFUs) are a serious complication of diabetes, often leading to chronic infections, prolonged hospitalization, and, in severe cases, amputations. A major challenge in DFU treatment is the presence of polymicrobial biofilms, ...

07/28/2026

There are many new trends in the cosmetic market, from vitamin C serums to peptide complexes, but oxygen is one that seems to keep resurfacing.

Back in 2013, researchers published a study showing that dissolved oxygen applied to the skin reduced inflammation and had a positive effect on skin structure in healthy volunteers. That built on earlier research from 2010 showing oxygen can actually pe*****te deep into human skin, not just sit on the surface.

Long before oxygen became a mainstream skincare buzzword, this kind of foundational research was already being published.

As a biomaterials company, we pay close attention to research like this. It's a reminder that today's skincare trends often rest on science that's been sitting in journals for over a decade.

Read the studies here:

Kellar et al., 2013: https://pubmed.ncbi.nlm.nih.gov/23725301/

Roe et al., 2010: https://www.sciencedirect.com/science/article/abs/pii/S0022480409005666

The data from this study demonstrate that the dressing has no deleterious effects and stimulates beneficial effects on intact, nonwounded skin.

07/16/2026

A recent study published in the International Wound Journal highlights a key detail in how we think about chronic wound care.

Researchers compared topical oxygen therapy to standard moist wound care and found the oxygen therapy group had a much higher healing rate early on, 45.5 percent versus 11.4 percent at day 28. By week 12, both groups had similar overall closure rates.

But there's an important detail underneath that: patients receiving oxygen therapy still healed an average of 13.5 days faster, even once both groups mostly closed.

Faster healing isn't just a number. Chronic wounds are widely understood to carry real costs the longer they stay open, more time at risk of infection, more pain, more disruption to daily life. Nearly two weeks is a meaningful difference for the person living with it.

Read the full study here: https://onlinelibrary.wiley.com/doi/10.1111/iwj.70837

Although topical oxygen therapy (TOT) is a promising treatment for chronic wounds, its clinical efficacy and safety remain to be rigorously established. We conducted a two-arm randomised controlled t...

07/04/2026

Happy 4th from the Aethl Bio team!

We're taking today to slow down, spend time with family, and enjoy the celebration.

Grateful for our team, our partners, and everyone who's been part of this year with us. Have a great weekend!

07/03/2026

Big news: we're heading to Nashville this August for the Annual Scientific Meeting, The National!

Our team is looking forward to connecting with the people working every day to help patients heal.

Will you be there too?

07/01/2026

The five-year mortality rate from a diabetic foot ulcer is 50%, which is significantly higher than colorectal cancer at 35%, breast cancer at 11%, and prostate cancer at 3%.

Despite the fact that 1 in 5 patients with a diabetic foot ulcer will require an amputation, the modern healthcare ecosystem still lacks a standardized clinical pathway for consistent diagnosis and treatment.

Our new white paper, A Wound That Won't Heal, addresses this foundational crisis. At Aethl, we believe that highlighting these stark clinical disparities is an essential step toward building a safer, more predictable framework for patient recovery.

Read the full paper here: https://aethl.com/white-papers/wound-that-wont-heal/

06/24/2026

The primary demographic for chronic wounds is the elderly, and across OECD nations, the elderly population is rapidly growing.

By 2050, more than 1 in 4 people in the EU will be aged 65 or older. The U.S. share aged 65 and older will rise from 17% to 23% by 2060, while Asia's older population is projected to nearly triple.

These shifting numbers show that current healthcare systems are not built for the demographic curve ahead.

At Aethl, we believe that understanding these global population changes is a critical step toward building more resilient, long-term care frameworks for the future.

Read the full paper here: https://aethl.com/white-papers/wound-that-wont-heal/

06/16/2026

Big news from the Aethl Bio team! 🚀

We have officially executed a definitive Manufacturing and Supply Agreement with Pure Source, LLC.

This long-term partnership combines Aethl Bio’s advanced platforms for wound care and wellness with Pure Source’s FDA-registered, cGMP-certified manufacturing capabilities.

This marks a significant step forward in our commercial roadmap, giving us the operational depth and quality systems required to bring our product vision to life. We’re excited to continue this journey and deliver on our mission to help people heal deeply and live fully.

Read the full release: https://www.einpresswire.com/article/919881469/aethl-bio-and-the-pure-source-execute-definitive-manufacturing-and-supply-agreement-formalizing-long-term-partnership

06/10/2026

Chronic wounds are a silent epidemic hiding in plain sight.

The impact on our healthcare system is profound:

*The U.S. annual cost of pressure ulcers stands at $28.6B

*Annual Medicare spend on chronic wound patients reaches $22.5B

*1 in 6 Medicare beneficiaries lives with a chronic wound

*1 in 10 hospitalized U.S. patients has a pressure ulcer at any given time

These figures represent a significant challenge for modern healthcare infrastructure. At Aethl, we believe that analyzing this data is a necessary first step toward developing more sustainable paths to recovery.

Read our full white paper here: https://aethl.com/white-papers/wound-that-wont-heal/

06/03/2026

A "healed wound," clinically, means the surface has closed. It does not mean the skin barrier underneath is functional.

Our new white paper looks at the diagnostic gap behind chronic wound recurrence:

*Only 3 of 70+ FDA-approved wound products are intended for non-healing chronic wounds*

*There is a 50% to 76% recurrence rate for venous leg ulcers*

*Only 2 of 8 venous-disease quality-of-life tools meet robust quality criteria*

These metrics highlight a clear diagnostic challenge in modern medicine. At Aethl, we believe that bringing visibility to these data gaps is a crucial step toward building a more robust recovery framework.

Read the full paper here: https://aethl.com/white-papers/wound-that-wont-heal/